Ozempic Is Finally Turning the Tide Against Obesity, New Data Shows

Key Points:

• Recent data from EPIC Research shows a significant increase in GLP-1 drug prescriptions, such as semaglutide found in Ozempic and Wegovy, with prescriptions rising more than fourfold in the U.S. between 2021 and 2026.
• This rise in GLP-1 usage coincides with a modest but sustained decline in obesity rates within the studied population, dropping from 42% to 41%, and even more among those prescribed GLP-1s, from 75% to 69%.
• While the data is not fully representative of the entire U.S. population, it aligns with CDC reports indicating a recent decrease in adult obesity rates and increased adoption of GLP-1 medications nationwide.
• Despite their effectiveness, only about 12% of Americans currently use GLP-1 drugs, with some discontinuing due to side effects, high costs, or lack of insurance coverage, though prices have recently decreased and cheaper generics may become available in the next five years.
• The future impact of GLP-1 drugs on obesity depends on broader adoption, affordability, and individual willingness to use them, but they hold potential to significantly reduce obesity prevalence over time.